NanoViricides, Inc. (NYSE American: NNVC) has received regulatory approval from ACOREP, the local regulatory agency in the Democratic Republic of Congo (DRC), to initiate a Phase II clinical trial of NV-387 Oral Gummies for the treatment of the current Bundibugyo ebolavirus outbreak and other Ebola viruses. The company has engaged Om Sai Clinical Research Private Limited as the contract research organization, with initial trial preparations already underway to expedite first patient dosing. Sufficient quantities of the oral gummies are already in the DRC, according to the company.
NV-387 is an investigational broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. The oral formulation could offer significant advantages in resource-limited outbreak settings compared with treatments requiring infusion, which are often logistically challenging in remote areas. The company cited World Health Organization data showing 4,141 confirmed cases and 1,889 confirmed deaths from the current Bundibugyo ebolavirus outbreak in the DRC as of Aug. 6, 2026.
This approval is a critical step for NanoViricides as it seeks to address an urgent public health need. The Ebola virus is highly lethal, and current treatments like monoclonal antibodies require intravenous administration, limiting their use in areas with scarce medical infrastructure. An oral therapy could be administered more easily, potentially improving patient outcomes and containment efforts.
NanoViricides' platform technology, based on TheraCour nanomedicine, aims to create nanoviricide drug candidates that target viruses directly. The company holds a worldwide exclusive perpetual license to this technology for multiple viral diseases, including Ebola and Marburg viruses. The successful development of NV-387 could not only provide a new tool against Ebola but also validate the broader nanoviricide approach for other viral infections.
The trial's initiation is a milestone for NanoViricides, which has been focused on advancing NV-387 into Phase II human clinical trials. The company's lead drug candidate is also being developed for RSV, COVID, Long COVID, Influenza, and other respiratory infections, as well as MPOX and measles. This Ebola trial represents a significant expansion of its clinical pipeline.
The approval also underscores the importance of international collaboration in pandemic preparedness. By partnering with a local CRO and ensuring drug availability in the DRC, NanoViricides is positioning the trial to generate real-world data in an active outbreak setting. This approach could accelerate the development of an effective oral treatment for Ebola, which remains a major global health concern.
Investors will be watching the trial's progress closely, as positive results could have substantial implications for the company's future. However, as with all drug development, there are risks: the candidate must demonstrate sufficient safety and efficacy in humans. NanoViricides acknowledges these uncertainties, noting that the path to regulatory approval is lengthy and capital-intensive.
The announcement comes at a time when the global community is increasingly focused on combating emerging infectious diseases. An oral Ebola treatment could be a game-changer, offering a practical solution for outbreak response in low-resource settings. This trial represents a step toward that goal, with potential benefits extending beyond Ebola to other viral threats.
